-
Something wrong with this record ?
Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy
J. Karolová, D. Kazantsev, M. Svatoň, L. Tušková, K. Forsterová, D. Maláriková, K. Benešová, T. Heizer, A. Dolníková, M. Klánová, L. Winkovska, K. Svobodová, J. Hojný, E. Krkavcová, E. Froňková, Z. Zemanová, M. Trněný, P. Klener
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 1998 to 1 year ago
Wiley Free Content
from 1996 to 1 year ago
PubMed
37605345
DOI
10.1002/ajh.27044
Knihovny.cz E-resources
- MeSH
- Adult MeSH
- Genes, p16 MeSH
- Clonal Evolution genetics MeSH
- Humans MeSH
- Neoplasm Recurrence, Local MeSH
- Lymphoma, Mantle-Cell * diagnosis drug therapy genetics MeSH
- DNA Copy Number Variations MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Our knowledge of genetic aberrations, that is, variants and copy number variations (CNVs), associated with mantle cell lymphoma (MCL) relapse remains limited. A cohort of 25 patients with MCL at diagnosis and the first relapse after the failure of standard immunochemotherapy was analyzed using whole-exome sequencing. The most frequent variants at diagnosis and at relapse comprised six genes: TP53, ATM, KMT2D, CCND1, SP140, and LRP1B. The most frequent CNVs at diagnosis and at relapse included TP53 and CDKN2A/B deletions, and PIK3CA amplifications. The mean count of mutations per patient significantly increased at relapse (n = 34) compared to diagnosis (n = 27). The most frequent newly detected variants at relapse, LRP1B gene mutations, correlated with a higher mutational burden. Variant allele frequencies of TP53 variants increased from 0.35 to 0.76 at relapse. The frequency and length of predicted CNVs significantly increased at relapse with CDKN2A/B deletions being the most frequent. Our data suggest, that the resistant MCL clones detected at relapse were already present at diagnosis and were selected by therapy. We observed enrichment of genetic aberrations of DNA damage response pathway (TP53 and CDKN2A/B), and a significant increase in MCL heterogeneity. We identified LRP1B inactivation as a new potential driver of MCL relapse.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016102
- 003
- CZ-PrNML
- 005
- 20250521101542.0
- 007
- ta
- 008
- 231013s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ajh.27044 $2 doi
- 035 __
- $a (PubMed)37605345
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Karolová, J $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Department of Medicine - Hematology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000338286000
- 245 10
- $a Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy / $c J. Karolová, D. Kazantsev, M. Svatoň, L. Tušková, K. Forsterová, D. Maláriková, K. Benešová, T. Heizer, A. Dolníková, M. Klánová, L. Winkovska, K. Svobodová, J. Hojný, E. Krkavcová, E. Froňková, Z. Zemanová, M. Trněný, P. Klener
- 520 9_
- $a Our knowledge of genetic aberrations, that is, variants and copy number variations (CNVs), associated with mantle cell lymphoma (MCL) relapse remains limited. A cohort of 25 patients with MCL at diagnosis and the first relapse after the failure of standard immunochemotherapy was analyzed using whole-exome sequencing. The most frequent variants at diagnosis and at relapse comprised six genes: TP53, ATM, KMT2D, CCND1, SP140, and LRP1B. The most frequent CNVs at diagnosis and at relapse included TP53 and CDKN2A/B deletions, and PIK3CA amplifications. The mean count of mutations per patient significantly increased at relapse (n = 34) compared to diagnosis (n = 27). The most frequent newly detected variants at relapse, LRP1B gene mutations, correlated with a higher mutational burden. Variant allele frequencies of TP53 variants increased from 0.35 to 0.76 at relapse. The frequency and length of predicted CNVs significantly increased at relapse with CDKN2A/B deletions being the most frequent. Our data suggest, that the resistant MCL clones detected at relapse were already present at diagnosis and were selected by therapy. We observed enrichment of genetic aberrations of DNA damage response pathway (TP53 and CDKN2A/B), and a significant increase in MCL heterogeneity. We identified LRP1B inactivation as a new potential driver of MCL relapse.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a lymfom z plášťových buněk $x diagnóza $x farmakoterapie $x genetika $7 D020522
- 650 _2
- $a variabilita počtu kopií segmentů DNA $7 D056915
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 _2
- $a geny p16 $7 D019942
- 650 _2
- $a klonální evoluce $x genetika $7 D060965
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kazantsev, D $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Svatoň, M $u CLIP - Childhood Leukaemia Investigation Prague, Department of Pediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Tušková, L $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Forsterová, K $u First Department of Medicine - Hematology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Maláriková, Diana $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Department of Medicine - Hematology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0332458
- 700 1_
- $a Benešová, K $u First Department of Medicine - Hematology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Heizer, T $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Dolníková, A $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Klánová, M $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Department of Medicine - Hematology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Winkovska, L $u CLIP - Childhood Leukaemia Investigation Prague, Department of Pediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Svobodová, K $u Center for Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Hojný, J $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Krkavcová, E $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Froňková, E $u CLIP - Childhood Leukaemia Investigation Prague, Department of Pediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Zemanová, Z $u Center for Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Trněný, M $u First Department of Medicine - Hematology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Klener, P $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Department of Medicine - Hematology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000177869378 $7 xx0105452
- 773 0_
- $w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 98, č. 10 (2023), s. 1627-1636
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37605345 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20250521101540 $b ABA008
- 999 __
- $a ok $b bmc $g 1999927 $s 1202464
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 98 $c 10 $d 1627-1636 $e 20230821 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
- LZP __
- $a Pubmed-20231013
